Braveheart Bio (BRVE) Q2 2026 earnings summary

Executive summary

• Clinical-stage biopharma advancing BHB-1893, a next-gen oral cardiac myosin inhibitor, with global Phase 3 trials underway for both obstructive and non-obstructive HCM; first patient dosing in LIONHEART-HCM expected in 2026 and interim results in 2027.

• Announced positive Phase 2 results for BHB-1893 in non-obstructive HCM, showing significant improvements in cardiac biomarkers and function.

• No product revenue to date; operations funded by equity and preferred stock sales, with a recent IPO raising $404.5M net proceeds and $439.9M gross proceeds.

• Significant operating losses continue as R&D and G&A expenses increase with clinical advancement and public company transition.

Financial highlights

• Net loss for six months ended June 30, 2026: $29.3M; net loss for Q2 2026: $15.0M; net loss attributable to common stockholders for Q2 2026: $18.6M.

• Accumulated deficit as of June 30, 2026: $95.9M; cash and cash equivalents: $122.8M (pro forma $527.3M post-IPO).

• Research and development expenses: $22.0M for six months ended June 30, 2026; $11.1M for Q2 2026.

• General and administrative expenses: $8.9M for six months ended June 30, 2026; $4.8M for Q2 2026.

• Net loss per share (basic and diluted): $(4.61) for six months ended June 30, 2026; $2.51 for Q2 2026.

Outlook and guidance

• Cash runway, including IPO proceeds, is expected to fund operations and capital expenditures into 2029.

• Plans to initiate a global Phase 3 trial in non-obstructive HCM in the first half of 2027; interim analysis from LIONHEART-HCM Phase 3 trial anticipated in the second half of 2027.

• Anticipates continued increase in R&D and G&A expenses as clinical programs advance and commercialization infrastructure is built.